NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
IONA-MM
NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)
NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)
To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months
Sponsor
Sanofi
ClinicalTrials.gov Identifier: NCT04458831
Official Title: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
First Posted : July 7, 2020
Click here to see details on ClinicalTrials.gov
Drug: isatuximab SAR650984
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Carfilzomib
Locations
United States, Arkansas
United States, California
United States, Florida
United States, Kansas
United States, Maine
United States, Michigan
United States, Missouri
United States, New Jersey
United States, North Carolina
United States, Ohio
United States, South Carolina
United States, South Dakota
United States, Texas
Puerto Rico
Europe
Austria
Belgium
Netherlands
France
Germany
Italy
Switzerland
Asia
Japan